Back
About the Global Fund
People & Structures
Back
Funding Model
Investments & Results
-
Explore contributions, investments and results in our fight against AIDS, tuberculosis and malaria around the world.
- Data Explorer
- Funding Decisions
- Data Service
HIV & AIDS
Tuberculosis
Malaria
Back
News
-
12 January 2021
Global Fund signs a record-breaking $8.54 billion in grants -
22 December 2020
Global Fund has awarded $1 billion to support countries’ COVID-19 responses, but funding for this purpose is now fully deployed -
21 December 2020
Denmark, Norway and Sweden Support Global Fund’s COVID-19 Response By Contributing a Total US$45 million -
14 December 2020
Canada Contributes CAD 65 million to Global Fund’s COVID-19 Response
Updates
-
22 January 2021
Update for PRs on Placing Orders and Procuring COVID-19 Products in 2021 -
19 January 2021
Thematic Review now available on community healthcare in five countries -
15 January 2021
2020 Applicant Survey Shows High-Level of Satisfaction with Global Fund’s Application Process -
13 January 2021
COVID-19 Situation Report
Stories
-
26 January 2021
15 Years of (RED) -
18 December 2020
A Look Back at 2020 -
17 December 2020
Data saves lives. To end HIV, we must improve key population data collection now. -
10 December 2020
Put Human Rights at the Centre of our Battle Against COVID-19 -
10 December 2020
Kiki’s story: Defending transgender rights during COVID-19 in Cameroon -
02 December 2020
How the lessons the world learned in the fight against HIV can help us defeat COVID-19
Back
Featured Publication
Documents by type
Withdrawal of the Quality Assurance Information Notice 2016-02 regarding IPCA Ratlam Manufacturing Site
15 July 2019
The Quality Assurance Information Notice 2016-02 providing recommendations regarding the procurement and the distribution of finished pharmaceutical products using active pharmaceutical ingredients manufactured at IPCA Ratlam Manufacturing Site is withdrawn. This is to reflect the Sourcing and Supply Chain Department decision that no specific quality assurance requirements are currently implemented by Global Fund quality assurance on IPCA finished pharmaceuticals products.
The Global Fund uses cookies for anonymized statistics on website use and content performance to help us improve and adapt the website. To consent to the use of cookies, please click “Accept”. To learn more about your rights and options, please read our Privacy Statement.